The price of ENOV is predicted to go up 3.35%, based on the high correlation periods with PLAY. The similarity of these two price pattern on the periods is 97.57%.
ENOV
PLAY
Up: 3.35%Similarity: 97.57%
ENOV Revenue Forecast
ENOV EPS Forecast
ENOV FAQs
What is bull’s view on ENOV?
Enovis (ENOV) stock is currently trading at $38.65, with analysts maintaining a bullish outlook. Roth MKM's Jason Wittes has set a price target of $75.00, indicating a potential upside of nearly 94% due to strong growth prospects in the MedTech sector and robust 2025 guidance. Recent CEO transition news may introduce short-term volatility, but the company's fundamentals and analyst consensus of "Strong Buy" suggest significant long-term potential.
What is bear's view on ENOV?
ENOV stock currently trades at $38.65, near its 52-week low of $38.27, reflecting bearish sentiment. The CEO's retirement announcement may create uncertainty, while analysts maintain a bullish $75 price target, suggesting potential upside. However, weak momentum and pre-market declines (-3.46%) indicate near-term pressure.
What is ENOV revenue forecast for next quarter?
The market consensus for ENOV's revenue in the upcoming quarter is projected to be approximately $558.797M USD.
What is ENOV eps forecast for next quarter?
The market consensus for ENOV's eps in the upcoming quarter is projected to be approximately $0.72 USD.
JMP Securities initiated coverage of Enovis with an Outperform rating and $62 price target. The analyst believes the recent LimaCorporate transaction is now "largely de-risked," and that the cost savings and sales synergies that are on the way are not reflected in the stock's current valuation. With the deal's close at the beginning of the year, Enovis' fiscal 2024 results have thus far reflected expected integration related headwinds that have tempered the company's true growth and earnings potential, which should come to fruition in 2025 and beyond, the analyst tells investors in a research note.